An interventional study of Magnetic Resonance Imaging and Ultra-High Resolution Computed Tomography (CT) Scan in COVID-19 and COVID Long-Haul, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Johns Hopkins University · Not applicable, Interventional, and Other
COVID-19 is a systemic inflammatory disease involving many organs including the lungs, vascular system liver and myocardium that lead to severe pathologies. Patients with severe cardiopulmonary symptoms usually require weeks to months to fully recover. Studies of clinical and subclinical impairments of COVID-19 patients are important for medical practice and public health as well as providing pathogenic insight to the viral infection and secondary immune response. Chronic damage of vital organs and systems, and the potential long-term effects is of serious concern. In this study the investigators plan to quantify and characterize chronic consequences of COVID-19 in individuals who receive similar medical care related to disease severity and duration in a single health care system. Using state-of-the-art Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) technology, we will study the pathology in major organ systems in comparison to matched controls. The results of this study may facilitate measures to prevent, detect, and manage complications from COVID-19 infections.
As the number of recovered COVID-19 patients increase around the globe, it is important to understand the longterm impact of the disease so that healthcare systems and providers can optimize follow-up care of these patients. Identifying long term effects may also help identify patients with an increased risk of major adverse events following discharge from the hospital. Currently, the long term effects of COVID-19 in discharged hospitalized patients remain unknown. Infection with COVID-19 may result in involvement of many organ systems, including the lung, heart, brain, liver, and kidneys. Patients with a previous history of cardiovascular disease have been found to be at higher risk for incident cardiovascular complications. Direct or indirect effects of COVID-19 infection may predispose patients to thrombotic events including acute myocardial injury or pulmonary defects. Cardio-pulmonary features of COVID-19 include: bilateral multilobar ground-glass opacifications, septal thickening, bronchiectasis, pleural thickening, and subpleural involvement. Gradual resolution of consolidative opacities and other imaging patterns associated with clinical improvement usually occur after the second week of the disease. Characterization and quantification of organ injury as well associated organ dysfunction may help facilitating appropriate prevention and management.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 206 is above the median of 100 across 4,099 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Johns Hopkins University is the lead sponsor of 1,783 studies on the registry; 313 are open to participants now.
Of its 203 completed or terminated interventional studies of FDA-regulated products, 140 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants who were hospitalized due to their COVID-19 illness.
Other: Magnetic Resonance Imaging · Other: Ultra-High Resolution Computed Tomography (CT) Scan
Participants who had COVID-19 but did not require hospitalization secondary to their illness.
Other: Magnetic Resonance Imaging · Other: Ultra-High Resolution Computed Tomography (CT) Scan
Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.
Completion of a high resolution CT scan of the lungs and high resolution CT of the coronary arteries.
Degree and extent of fibrosis
\- MRI to assess degree and extent of fibrosis in the liver, lungs, brain, myocardium, and vascular systems
Time frame: Analyzed within 6 months of study completion
Assessment of Perfusion
Ultra-High Resolution CT to assess the amount of perfusion to the lungs and heart.
Time frame: Analyzed within 6 months of study completion
Plan to share: Yes — Data obtained through this study may provided to qualified researchers with academic interest in COVID-19. Data shared will not contain any personal health information (PHI). A statement of work and data use agreement are pre-requisites for data sharing.
Supporting information: Study protocol, Sap, Csr, Analytic code
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johns Hopkins University